In the recent years, multiple randomized controlled studies (RCT) have been conducted to approve different pharmacological classes viz., endothelin receptor antagonists, phosphodiesterase type-5 inhibitors, and prostanoids. All these classes have their benefits and limitations. Pulmonary hypertension is a very heterogeneous condition, with pulmonary arterial hypertension being the quintessential diagnosis. Newly approved treatments for PAH has been assessed in clinical trials. Following points give information about benefits or limitations of particular drugs.
Current Therapeutic Targets: ET-receptor Antagonists: ET-1 has a dominant role in the physiopathology of PAH, acting as a potent vasoconstrictor and promoting the PASMCs proliferation. ET-1 is overexpressed in plasma and lung tissue of PAH patients. Current oral ET-receptor antagonists (ERAs) include bosentan and ambrisentan. Both…
